Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.72
-6.39 (-3.04%)
AAPL  266.72
+2.14 (0.81%)
AMD  196.09
-4.06 (-2.03%)
BAC  51.09
-1.98 (-3.72%)
GOOG  313.71
-1.19 (-0.38%)
META  642.92
-12.74 (-1.94%)
MSFT  385.76
-11.47 (-2.89%)
NVDA  190.87
+1.05 (0.55%)
ORCL  138.90
-9.19 (-6.20%)
TSLA  398.46
-13.36 (-3.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.